Press Releases

The global market for anxiety and depression treatment products is anticipated to grow at a significant pace i.e., USD 19.3 billion during the forecast period 2023-2030. There is an increase in awareness about mental health issues and their treatment, an increasing number of product approvals, and a huge population suffering from anxiety and depression are the key drivers for the growth of the anxiety and depression treatment market. Moreover, the rising awareness among the end-users and advancement in the healthcare segment, especially in the emerging economies will enhance the growth of the overall market in the forecast period. Furthermore, the adoption of the latest technologies and treatments will provide growth opportunities for the market players, thus supporting the growth of the global anxiety disorders and depression treatment market in the forecast period.

The continuous successful result of clinical trials for drugs and their commercialization will propel the future growth of antidepressant drugs. The COVID-19 pandemic has created many opportunities as there is a deterioration of mental health due to the coronavirus.

Browse 53 market data Tables and 37 Figures spread through 110 Pages and in-depth TOC on “Anxiety and Depression Treatment Market by by Product (Antidepressant Drugs(SSRIs, SNRIs, TCAs, MAOIs, Atypical Antipsychotics, Benzodiazepins, Anticonvulsants, Beta-Blockers, and Others ) and Therapy and Devices (Fisher Wallace Stimulator, TMS, VNS, ECT, CBT, and Others)), by Indication (MDD, OCD, Phobias, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and Geography (U.S., Canada, Germany, U.K., France, China, Japan, India, and Rest of the World) - Global Forecast to 2030"

In December 2022, Novartis AG acquired Cadent Therapeutics. The acquisition will add two new drugs, which include CAD-9303, an NMDAr positive allosteric modulator; and MIJ-821, an NMDAr negative allosteric modulator, which is in the clinical trial stage in the former’s portfolio for neurology and psychiatry.

Due to Increasing Product Launches, Drugs Category Dominates the Market

On the basis of product, the drugs segment holds the largest market share in the anxiety and depression market and will retain its position during the forecast period. This is because of the increase in the number of mental disorder cases, the rising number of product launches, and awareness by health institutions about mental diseases. Moreover, SSRIs and beta-blockers will grow in the forecast period because of stress in the work environment and changes in consumer lifestyles.

Global Anxiety and Depression Treatment Market Segmentation Analysis

Segment	Categorization	Leading Category
Product	Antidepressant Drugs and Therapies	Antidepressant Drugs (Largest)     Therapies (Fastest)
Indication	MDD, OCD, Phobias, Others	MDD (High CAGR)
Distribution Channel	Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies	Hospital Pharmacies (Largest share)
Region	North America, Europe, Asia-Pacific, and Rest of the World	North-America (Largest)

Download Free Sample Copy of this Research Report Global Anxiety and Depression Treatment Market

Scope of the Report

Report Metric	Details
Market Size Available for the Years in the Study	2018–2030
Historical Period	2018–2022
Base Year	2022
Forecast Period	2023–2030
Segments Covered in the Study	Product, Indication, Distribution Channel, and Region
Geographies Covered in the Study	North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Spain, Russia), Asia-Pacific (China, Japan, India, South Korea), and Rest of the World (Brazil, Saudi Arabia, South Africa, U.A.E.)
Companies Covered in the Study	Eli Lily and Company, Forest Laboratories, Inc., Johnson and Johnson Private Limited, GlaxoSmithKline plc., H. Lundbeck A/S, Pfizer,Inc., Merck & Co. Inc., Inc., Sanofi S.A., Astra Zeneca plc., and Bristol Myers Squibb Company

Geography Insight

Geographically, North America is anticipated to hold the largest market share in the anxiety and depression treatment market. This is due to the rise in cases of pain, the huge population suffering from anxiety and stress-related disorders, and awareness about mental health. Europe is considered to be the second-largest growing regional anxiety disorders and depression treatment market as a result of an increase in public awareness of anxiety disorders and treatments.  The Asia Pacific is projected to have healthy growth in the coming few years because of the rising prevalence of psychiatric disorders.

Key Takeaway from the Report:

• Among all the product, the drugs segment will hold the largest market share in the anxiety and depression market.
• Due to high Patient Influx, hospital pharmacies segment will lead the market.

The Report Offers:

• Historical market estimate for the years 2018–2022 and forecast for the years 2023–2030
• Insight on current market trends, market dynamics, key opportunities and major challenges in the industry
• Market insights by in-depth segmentation with industry dynamics.
• Competitive analysis and benchmarking of the industry leaders and their product offerings
• Profiles of leading players and innovators, their financial overview and product portfolio
• Analysis of key industry trends and recent developments
• Value chain analysis and distribution channel analysis with opportunity assessment
• Market share analysis of major players

Benefits of Report Purchase from VynZ:

Detailed Research

We provide accurate data and in-depth analysis with all-inclusive coverage.

Robust Research Methodology

Robust research methodology and data triangulation to ensure high quality report.

Analyst Support

24*7 analyst support – Pre and post purchase of the report as well as during the project tenure.

Sales Support

24*7 sales support – Hassle free delivery of the report and quick response and support by sales team.

Free Customization

20% post purchase free customization to meet your requirements.

Customer Satisfaction

We claim full customer satisfaction as our core values lie in building long term relationship.

Security

High level of data security and confidentiality of your information.

The report provides the market value for the base year 2020 and a yearly forecast till 2027 in terms of revenue (USD Million). The report segments the global Anxiety and Depression market on the basis of product, indication type, distribution channel, and region.

Global Anxiety and Depression Treatment Market Coverage

Product Insight and Forecast 2018-2030

• Antidepressant Drugs
  • SSRIs 
  • SNRIs 
  • TCAs 
  • MAOIs 
  • Atypical Antipsychotics
  • Benzodiazepins
  • Anticonvulsants
  • Beta-Blockers
  • Others
• Therapy & Devices
  • Fishcer Wallace Stimulator
  • TMS 
  • VNS
  • ECT 
  • CBT
  • Others

Indication Insight and Forecast 2018-2030

• MDD 
• OCD 
• Phobias
• Others

Distribution Channel Insight and Forecast 2018-2030

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Geographical Segmentation

Anxiety and Depression Treatment Market by Region

North America

• By Product
• By Indication
• By Distribution Channel
• By Country – U.S., Canada, and Mexico

Europe

• By Product
• By Indication
• By Distribution Channel
• By Country – Germany, U.K., France, Italy, Spain, and Rest of Europe

Asia-Pacific (APAC)

• By Product
• By Indication
• By Distribution Channel
• By Country – China, Japan, India, South Korea, Singapore, and Rest of Asia-Pacific

Rest of the World (RoW)

• By Product
• By Indication
• By Distribution Channel
• By Country – Brazil, Saudi Arabia, South Africa, U.A.E., and Other Countries